| Bispecific antibody that binds to CD38 and CD3 |
2023-1-30 |
2023-4-12 |
|
| Complement component C5 antibody |
2022-11-14 |
2023-2-09 |
|
| Bispecific checkpoint inhibitor antibodies |
2022-9-28 |
2023-2-09 |
|
| B-cell maturation antigen (bcma) binding domain compositions |
2022-9-27 |
2023-3-30 |
|
| Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to … |
2022-9-22 |
2022-11-30 |
|
| IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS |
2022-9-13 |
2022-12-06 |
|
| Anti-tslpr (crlf2) antibodies |
2022-8-27 |
2023-3-02 |
|
| Anti-tslpr (crlf2) antibodies |
2022-8-27 |
2023-4-06 |
|
| Heterodimeric antibodies that bind to cd3 and tumor antigens |
2022-8-19 |
2022-11-09 |
|
| Il-12 heterodimeric fc-fusion proteins |
2022-8-11 |
2023-1-26 |
|
| Prostate cancer treatment or treatment of gynecologic or genitourinary … |
2022-8-05 |
2023-2-09 |
|
| Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells … |
2022-8-03 |
2023-2-09 |
|
| Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood … |
2022-7-27 |
2023-2-02 |
|
| Il-18-fc fusion proteins |
2022-7-26 |
2023-2-02 |
|
| Trispecific antibodies |
2022-7-22 |
2023-3-23 |
|
| Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer |
2022-7-21 |
2022-9-01 |
|
| Bispecific binding agents binding to cldn18.2 and cd3 |
2022-6-15 |
2022-12-22 |
|
| Heterodimeric antibodies that bind claudin18.2 and cd3 |
2022-6-15 |
2022-12-22 |
|
| Dosing of a bispecific antibody that binds cd20 and cd3 |
2022-6-03 |
2023-2-16 |
|
| Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination … |
2022-6-02 |
2023-2-23 |
|
| Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint … |
2022-5-24 |
2022-7-29 |
|
| Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE |
2022-5-23 |
2023-2-23 |
|
| Fc VARIANTS WITH ALTERED BINDING TO FcRn |
2022-5-17 |
2022-9-08 |
|
| Heterodimeric antibodies that bind cd3 and cd38 |
2022-5-04 |
2022-12-22 |
|
| Novel ctla4-ig immunoadhesins |
2022-5-04 |
2022-11-03 |
|
| Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties |
2022-4-06 |
2022-6-01 |
|
| Heterodimeric proteins |
2022-3-23 |
2023-2-23 |
|
| Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
2022-3-16 |
2022-6-30 |
|
| Heterodimeric antibodies that bind cd3 and gpc3 |
2022-3-10 |
2022-9-15 |
|
| Heterodimeric antibodies that bind cd3 and cldn6 |
2022-3-09 |
2022-9-15 |
|
| tafasitab |
2022-2-22 |
2022-3-22 |
|
| Heterodimeric antibodies that bind somatostatin receptor 2 |
2022-2-03 |
2022-5-13 |
|
| ENGINEERED IL-2 Fc FUSION PROTEINS |
2022-1-18 |
2022-7-07 |
|
| Heterodimeric proteins |
2022-1-17 |
2022-4-12 |
|
| Icos targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion … |
2021-12-23 |
2022-6-30 |
|
| Novel heterodimeric proteins |
2021-12-21 |
2022-1-27 |
|
| Anti-cd28 compositions |
2021-12-21 |
2022-4-21 |
|
| Fc VARIANTS WITH ALTERED BINDING TO FcRn |
2021-12-13 |
2022-4-14 |
|
| Heterodimeric antibodies that bind cd3 and tumor antigens |
2021-12-03 |
2022-5-26 |
|
| Heterodimeric antibodies that bind tgfbrii |
2021-11-05 |
2022-5-12 |
|
| Anti-cd20 antibodies and therapeutic uses thereof |
2021-10-22 |
2022-4-28 |
|
| Fc VARIANTS WITH ALTERED BINDING TO FcRn |
2021-10-19 |
2022-2-01 |
|
| Bispecific antibodies that bind pd-l1 and cd28 |
2021-10-14 |
2022-4-21 |
|
| Biomarkers, methods, and compositions for treating autoimmune disease including … |
2021-10-06 |
2022-4-14 |
|
| Heterodimeric antibodies that bind enpp3 and cd3 |
2021-8-31 |
2021-10-31 |
|
| Methods and compositions for inhibiting cd32b expressing cells |
2021-8-30 |
2021-12-23 |
|
| TARGETED HETERODIMERIC Fc FUSION PROTEINS CONTAINING IL-15 IL-15alpha AND … |
2021-7-02 |
2022-3-10 |
|
| Optimized antibody variable regions |
2021-6-04 |
2022-12-01 |
|
| Heterodimeric antibodies that bind prostate specific membrane antigen (psma) … |
2021-5-14 |
2021-11-18 |
|
| Heterodimeric antibodies that bind msln and cd3 |
2021-5-14 |
2023-3-22 |
|
| Heterodimeric antibodies that bind CD3 and tumor antigens |
2021-5-13 |
2021-6-10 |
|
| Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint … |
2021-4-16 |
2021-8-19 |
|
| Heterodimeric antibodies that bind fibroblast activation protein |
2021-4-16 |
2021-8-19 |
|
| Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
2021-3-22 |
2022-2-10 |
|
| Bispecific Antibodies That Bind To CD38 and CD3 |
2021-2-25 |
2021-4-15 |
|
| Anti-steap1 antigen binding protein |
2021-1-20 |
2021-1-29 |
|
| Bispecific antibodies that bind cd123 and cd3 |
2020-12-16 |
2021-5-20 |
|
| Heterodimeric proteins |
2020-11-02 |
2021-6-10 |
|
| Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15rα fc-fusion … |
2020-10-15 |
2020-11-30 |
|
| Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15rα fc-fusion … |
2020-10-15 |
2020-11-30 |
|
| Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15rα fc-fusion … |
2020-10-15 |
2020-11-30 |
|
| HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS |
2020-10-12 |
2021-9-16 |
|
| IL-15/IL-15Ra FC FUSION PROTEINS ACTING ON PD-1 WITH ENHANCED PROPERTIES |
2020-10-09 |
2022-2-02 |
|
| Targeted il-12 heterodimeric fc-fusion proteins |
2020-10-02 |
2021-4-08 |
|
| Targeting IL-12 heterodimeric Fc fusion proteins |
2020-10-02 |
2023-4-04 |
|
| Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions |
2020-8-10 |
2021-7-08 |
|
| HETERODIMERIC IgG-LIKE BISPECIFIC ANTIBODIES |
2020-8-06 |
2021-5-06 |
|
| Fc VARIANTS WITH ALTERED BINDING TO FcRn |
2020-8-04 |
2021-4-22 |
|
| OPTIMIZED Fc VARIANTS |
2020-7-29 |
2021-5-13 |
|
| A method for purifying antibodies |
2020-7-21 |
2020-8-06 |
|
| Bispecific antibodies that bind cd20 and cd3 |
2020-7-10 |
2021-4-01 |
|
| IL-7-FC-fusion proteins |
2020-5-15 |
2022-11-29 |
2022-11-29 |
| Dosing of a bispecific antibody that binds pd1 and ctla4 |
2020-3-27 |
2022-2-09 |
|
| Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint … |
2020-3-16 |
2021-4-01 |
|
| Untargeted and targeted il-10 fc-fusion proteins |
2020-2-21 |
2021-12-29 |
|
| Compositions and methods for treating IgE-mediated disorders |
2020-2-05 |
2023-1-31 |
2023-1-31 |
| Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d … |
2019-12-20 |
2021-10-27 |
|
| Modulation of t cells with bispecific antibodies and fc fusions |
2019-12-19 |
2020-10-29 |
|
| Treatment for chronic lymphocytic leukemia (cll) |
2019-11-29 |
2020-4-09 |
|
| Bispecific antibodies that bind cd 123 cd3 |
2019-11-26 |
2020-1-30 |
|
| Heterodimeric Fc variants |
2019-8-13 |
2022-8-02 |
2022-8-02 |
| ANTI-STEAP1 ANTIGEN BINDING PROTEIN |
2019-7-02 |
2021-3-31 |
|
| Dosing of a bispecific antibody that bind cd123 and cd3 |
2019-6-03 |
2019-12-05 |
|
| Dosing of a bispecific antibody that bind cd123 and cd3 |
2019-4-26 |
2021-7-29 |
|
| Methods of treating neurological diseases |
2019-4-01 |
2020-6-04 |
|
| Optimized fc variants and uses thereof |
2019-3-21 |
2019-5-30 |
|
| Modulation of t cells with bispecific antibodies and fc fusions |
2019-3-08 |
2019-6-27 |
|
| Fc Variants with Increased Affinity for FcyRIIc |
2018-9-21 |
2019-3-07 |
|
| Heterodimeric antibodies that bind cd3 and psma |
2018-6-05 |
2018-7-31 |
|
| Bispecific antibodies that bind cd20 and cd3 |
2018-6-01 |
2018-12-06 |
|
| Novel immunoglobulin variants |
2018-1-29 |
2018-12-20 |
|
| IL15/IL15Ra HETERODIMERIC FC-FUSION PROTEINS |
2017-10-16 |
2019-8-29 |
|
| IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS |
2017-10-16 |
2022-10-28 |
|
| IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS |
2017-10-16 |
2022-10-28 |
|
| Treatment for chronic lymphocytic leukemia (cll) |
2017-9-14 |
2018-2-08 |
|
| Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint … |
2017-8-30 |
2019-8-29 |
|
| Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint … |
2017-8-30 |
2018-3-08 |
|
| Rapid clearance of antigen complexes using novel antibodies |
2017-8-21 |
2018-7-19 |
|
| Antibodies with modified isoelectric points |
2017-7-12 |
2017-7-27 |
|
| Heterodimeric antibodies that bind somatostatin receptor 2 |
2017-6-28 |
|
|